Ventana and Astellas in automated tissue diagnostics pact

Subscribe via: RSS

Big pharma, Diagnostics, Partnering, Pharma

Ventana and Astellas in automated tissue diagnostics pact

Posted on 15 April 2015

Ventana Medical Systems has entered into master collaboration agreement with Astellas Pharma to develop novel automated tissue diagnostics in support of therapeutic compounds in development.

Initial projects related to this agreement will support early-stage clinical trials for the Astellas therapeutic compound ASP5878, a novel small-molecule fibroblast growth factor receptor (FGFR) inhibitor which has been shown to block the kinase activities of FGFR1, FGFR2, FGFR3 and FGFR4.

Searching for more deal information? Current Partnering offers the following options:

CP Reports | Browse titles | Over 200 report titles that focus upon different deal types from licensing, co-promotion to distribution, biomarkers to drug delivery, oncology to psychiatry, all of which provide you with an insight into the latest life science deal making trends
Current Agreements | Login | Find out more | Updated daily by our industry analysts, our fully searchable life sciences intelligence database allows you to find deals and alliances dating as far back as 2000 saving you valuable time on your deal making research activities
CP Knowledge Centre | Login | Find out more | Provides you with an all-in-one intelligence package that allows you to simultaneously access our CP reports, CP Insight and Current Agreements deal and alliances database, at the same time

Ventana will develop, in parallel, an immunohistochemistry (IHC) test identifying FGF19 in certain solid tumors.

Financial terms of this agreement were not disclosed.

For further deal information visit Current Agreements (subscription required)

View: Top pharmaceutical companies

View: Top biotech companies

Reports: Browse our extensive deal making report portfolio